Biohit Oyj
BIOBV.HE
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.23M
Close$
$0.53
76.2% downside
Current Fair Value
76.2% downsideOvervalued by 76.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $35.23 Million |
|---|---|
| Enterprise Value | $35.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.18 |
| Beta | 0.57 |
| Outstanding Shares | 15,205,593 |
Return
| Return on Equity | 32.72% |
|---|---|
| Return on Assets | 25.73% |
| Return on Invested Capital | 35.63% |
Valuation & Multiples
| P/E Ratio | 11.29 |
|---|---|
| PEG | 25.4 |
| Price to Sales | 2.23 |
| Price to Book Ratio | 2.23 |
| Enterprise Value to Revenue | 1.15 |
| Enterprise Value to EBIT | 5.65 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$7.90 M
Average shareholder expectationNext Earnings Call
Expected Date
February 17, 2027
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$8.47 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biohit Oyj
47 employees
CEO: Jussi Hahtela Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of d...